| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 133.0 | 122.1 |
| Profit before tax | 87.6 | 68.0 |
| Net income | 59.8 | 40.1 |
| EPS (diluted, $ a share) | $0.36 | $0.23 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +49.3% |
|---|---|
| Revenue, year on year | +9.0% |
| Operating margin | 70.0% |
10-Q filed with the SEC, NASDAQ: IRWD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Ironwood Pharmaceuticals Inc: key numbers
- Share price
- $4.87Close, Nov 17
- Market cap
- $806M
- Shares outstanding
- 165.55MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Ironwood Pharmaceuticals Inc
All →Ironwood Pharmaceuticals Financial Results
Ironwood Pharmaceuticals reported Q3 2026 total revenue of $133 million and GAAP net income of $60 million, driven by strong LINZESS U.S. net sales of $325 million. Due to strong performance, the company raised its full-year 2026 LINZESS U.S. net sales guidance to $1.20 - $1.25 billion and total revenue guidance to $485 - $510 million.
- Counterparty
- AbbVie Inc.
- Term
- Q3 2026
“Ironwood delivered a third consecutive strong quarter as we continue focused execution of our three strategic priorities: maximize LINZESS, advance apraglutide and deliver sustained profits and cash flows. We believe LINZESS is on its way to returning to blockbuster status for 2026 with year-to-date U.S. net sales already surpassing total 2025 U.S. net sales, primarily driven by improved net price and mid-single-digit prescription demand growth.”
Tom McCourt, Ironwood Chief Executive Officer
“In addition to driving strong financial performance, we are ramping up the STARS-2 confirmatory Phase 3 trial of apraglutide in people living with short bowel syndrome with intestinal failure. As we continue to add trial sites in the U.S., all of the planned clinical trial applications have been submitted to international health authorities and are now under review or already approved.”
Tom McCourt, Ironwood Chief Executive Officer
Ironwood Pharmaceuticals Leadership Change
Ironwood Pharmaceuticals appointed Tammi Gaskins, currently Senior Vice President and Chief Commercial Officer, as Chief Executive Officer and a director, effective January 1, 2027. She succeeds Thomas McCourt, who will retire as CEO on December 31, 2026, after 17 years with the company but will remain on the Board of Directors. Gaskins will receive an annual base salary of $775,000 and $4 million in target equity grant value as part of her new role.